Non-invasive ventilation (NIV) refers to respiratory support provided without endotracheal intubation. The most common modalities include continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), and high-flow nasal cannula (HFNC). These therapies aim to improve oxygenation, reduce the work of breathing, and potentially prevent invasive mechanical ventilation.
The post REBEL Core Cast 148.0–Demystifying Non-Invasive Ventilation & HiFlow appeared first on REBEL EM – Emergency Medicine Blog.
The content discusses the medical management of respiratory distress using non-invasive ventilation (NIV) and high flow nasal cannula (HFNC).
NIV provides ventilatory support without an invasive airway, using masks or nasal prongs. It includes continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP). NIV is indicated for conditions such as acute exacerbations of chronic obstructive pulmonary disease (COPD), acute cardiogenic pulmonary edema (ACPE), asthma, and in certain immunocompromised patients or post-extubation to prevent reintubation. Its physiological benefits involve reducing the work of breathing, improving gas exchange, and opening collapsed alveoli. Contraindications for NIV include cardiac arrest, immediate need for intubation, facial trauma, airway obstruction, high risk of aspiration, and decreased mental status that compromises airway protection.
High flow nasal cannula (HFNC) delivers heated and humidified oxygen at high flow rates. Its mechanism of action includes washing out physiological dead space, providing a small amount of positive end expiratory pressure, improving mucociliary clearance, and reducing the work of breathing. HFNC is primarily used for hypoxemic respiratory failure and can be an alternative to conventional oxygen therapy or even NIV in some situations, particularly post-extubation. It is often better tolerated than NIV, allowing patients to speak and eat.
The selection between NIV and HFNC depends on the patient’s underlying condition and specific needs. NIV is generally preferred for hypercapnic respiratory failure, such as in COPD exacerbations, and for acute cardiogenic pulmonary edema due to its capacity to deliver more significant ventilatory support and pressure. HFNC is effective for improving oxygenation in hypoxemic respiratory failure. Both therapies necessitate careful patient monitoring, including vital signs, gas exchange, and assessment of the work of breathing, to determine their effectiveness and identify signs of failure that may require escalation to intubation.
https://rebelem.com/rebel-core-cast-148-0-demystifying-non-invasive-ventilation-hiflow/?utm_source=rss&utm_medium=rss&utm_campaign=rebel-core-cast-148-0-demystifying-non-invasive-ventilation-hiflow
